This collaborative conference will:

• Stimulate basic, translational, and clinical research in CNS metastases;
• Engage clinical researchers in innovative trial designs for primary and secondary CNS malignancies;
• Address the needs of patients with intracranial tumors.

These areas of great unmet need will be addressed in a dynamic and interactive framework. The structure brings together various disciplines to emphasize basic and translational research on brain metastases as well as clinical trial design and outcomes in primary and metastatic intracranial tumors. Research highlighting novel approaches, innovative ideas, and recent advances in neuro-oncology clinical trials will be presented and discussed. There will be a unique opportunity for collaboration and exchange of ideas between those dedicated to the science and care of patients with primary and secondary malignancies of the CNS.

Unparalleled Networking Opportunities
This conference will provide a unique opportunity for establishing collegial relationships with other international professionals focused on improving outcomes for brain tumor patients. Against the backdrop of the vibrant city of San Francisco, the conference will provide an unparalleled platform to share scientific results, explore new treatment paradigms, develop new friendships and connect with new collaborators. The social highlight of the meeting will take place at the world-famous San Francisco Exploratorium, and will involve an evening fun, food, exploration, and dancing!

Early Career Professionals and Young Investigators Workshop
Join us Thursday afternoon, August 10th, prior to the Conference kicking off that evening, for this special half-day workshop. Sessions will address grant opportunities, career advancement, and more. Details to follow soon.

Evening at the Exploratorium!
The social highlight of the meeting will take place at the world-famous San Francisco Exploratorium. Join your colleagues for an evening of fun, food, exploration, and dancing.  Attendance is complimentary for all conference registrants!

Learning Objectives

• Explain new CNS-penetrant systemic agents in the context of multidisciplinary care for the treatment of CNS metastases.
• Discuss new developments in local therapeutic approaches and diagnostics in the treatment of CNS metastases.
• Explain the role of the tumor microenvironment in CNS metastases.
• Compare clinical trials designs incorporating recent advances such as liquid biopsy, novel prognostic biomarkers, and advanced neuroimaging for the treatment of CNS malignancies.
• Outline challenges for the development and approval of novel therapies for CNS cancers.

Who Should Attend
Neuro-oncologists (both neurology and medical oncology-trained), Medical Oncologists, Neurosurgeons, Neuro-radiologists, Neuropathologists, Neuropsychologists, Radiation Oncologists, Basic and Translational Scientists, Basic and Clinical Science Trainees, Allied Health Professionals, Palliative Care Professionals, Industry Professionals, Regulatory and Government Officials, Patient Advocates and Nursing Professionals.

Registration
Registration is now open. Click here to register today. SNO and ASCO members receive discounted registration rates. Take advantage of early bird pricing through Friday, June 30, 2023.

Abstract Submission
Each year the organizers of the Conference welcome the submission of original research and clinical findings addressing CNS basic science research and clinical trials. This includes previously presented or not yet presented clinical trial abstracts (encore) and trials in progress. All submissions are peer-reviewed and accepted abstracts are presented as oral talks or in-person posters. Electronic posters will be available online at the start of the Conference.

Abstract submission categories in 2023:

• Basic Science of Brain Metastases
• Basic Science of Leptomeningeal Disease
• Clinical Research Methods
• Local and Multimodality Approaches
• Neuroimaging
• Supportive Care/Health Outcomes (QOL, DEI, Survivorship, Nursing, Social Work)
• Systemic Therapeutics (including targeted therapy, immunotherapy, antibody-drug conjugates, novel therapies)
• Screening/Diagnostics/Prognostics
• Trials in Progress

The abstract submission site is now closed.
Accepted abstracts will be published and indexed in Neuro-Oncology Advances. 

Edits to abstracts cannot be made after the March 17, 2023 deadline. Abstract submitters should carefully check your abstract for content errors, spelling, names, etc. before submitting. SNO neither proofreads for nor corrects spelling, typographical, grammatical, or scientific errors.

Once the accepted abstracts are submitted to the journal for publication, requests for withdrawals cannot be processed. All request to withdraw abstracts MUST be received no later than Tuesday, May 23, 2023 at 11:59 PM ET.

Co-Chairs
Adrienne Boire, Memorial Sloan Kettering Cancer Center
Sarah Goldberg, Yale School of Medicine

Co-Chairs Elect
Priya Kumthekar, Northwestern Medicine
Hussein Tawbi, University of Texas MD Anderson Cancer Center

Immediate Past Co-Chairs
Priscilla Brastianos, Massachusetts General Hospital, Harvard Medical School
Mustafa Khasraw, Duke University

Planning Committee
Stephen Bagley, University of Pennsylvania
Evanthia Galanis, Mayo Clinic Rochester
Vinai Gondi, Northwestern Medicine Cancer Center Warrenville and Proton Center
Jona Hattangadi-Gluth, University of California, San Diego
Sara Hurvitz, University of California, Los Angeles
Emilie Le Rhun, University Hospital Zurich, Switzerland
Nancy Lin, Dana Farber Cancer Institute
Minesh Mehta, Miami Cancer Institute
Josh Neman, University of Southern California, Los Angeles
Michael Platten, University Medical Center Mannheim
Solmaz Sahebjam, National Cancer Institute, National Institutes of Health
Debra Nana Yeboa, University of Texas MD Anderson Cancer Center